Business Description
Cingulate Inc
NAICS : 325412
SIC : 2834
ISIN : US17248W3034
Total Employee Number:
14Description
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.49 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.39 | |||||
Debt-to-EBITDA | -0.31 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 77.6 | |||||
3-Year EPS without NRI Growth Rate | 77.1 | |||||
3-Year FCF Growth Rate | 77.9 | |||||
3-Year Book Growth Rate | -83.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 35.62 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.14 | |||||
9-Day RSI | 46.04 | |||||
14-Day RSI | 48.48 | |||||
3-1 Month Momentum % | -15.1 | |||||
6-1 Month Momentum % | 5.62 | |||||
12-1 Month Momentum % | 10.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.55 | |||||
Quick Ratio | 2.55 | |||||
Cash Ratio | 2.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -436.3 | |||||
Shareholder Yield % | -51.61 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -381.84 | |||||
ROA % | -168.19 | |||||
ROIC % | -289.05 | |||||
3-Year ROIIC % | -246.56 | |||||
ROC (Joel Greenblatt) % | -843.99 | |||||
ROCE % | -281.61 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.11 | |||||
Price-to-Tangible-Book | 3.11 | |||||
EV-to-EBIT | -1.97 | |||||
EV-to-Forward-EBIT | 0.53 | |||||
EV-to-EBITDA | -2.01 | |||||
EV-to-Forward-Revenue | 2.92 | |||||
EV-to-FCF | -2.43 | |||||
| Price-to-Net-Current-Asset-Value | 3.67 | |||||
| Price-to-Net-Cash | 4.21 | |||||
Earnings Yield (Greenblatt) % | -50.76 | |||||
FCF Yield % | -29.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CING
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cingulate Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -4.255 | ||
| Beta | -1.8431 | ||
| 3-Year Sharpe Ratio | -0.67 | ||
| 3-Year Sortino Ratio | -0.86 | ||
| Volatility % | 67.33 | ||
| 14-Day RSI | 48.48 | ||
| 14-Day ATR ($) | 0.421212 | ||
| 20-Day SMA ($) | 5.0605 | ||
| 12-1 Month Momentum % | 10.38 | ||
| 52-Week Range ($) | 3.16 - 11.89 | ||
| Shares Outstanding (Mil) | 13.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cingulate Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cingulate Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 125 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 51 days | ||
| General meeting for 2026 | 2026-07-09 10:00 | 4.84 (-2.22%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 4.92 (+1.65%) | ||
| Annual report for 2025 | 2026-03-18 | 11.66 (+5.52%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-18 | 11.66 (+5.52%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 3.80 (+3.83%) | ||
| 0.0833333:1 Stock Split | 2024-08-09 | 2.83 (-11.91%) | ||
| 0.05:1 Stock Split | 2023-11-30 | 74.40 (-4.32%) |
Show
Entries
Cingulate Inc Frequently Asked Questions
What is Cingulate Inc(CING)'s stock price today?
The current price of CING is $4.92. The 52 week high of CING is $11.89 and 52 week low is $3.16.
When is next earnings date of Cingulate Inc(CING)?
The next earnings date of Cingulate Inc(CING) is 2026-08-31 Est..
Does Cingulate Inc(CING) pay dividends? If so, how much?
Cingulate Inc(CING) does not pay dividend.
Guru Commentaries on NAS:CING
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQ: CING) | 2021-12-10 |
Articles on Cingulate Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers